Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency

NCT01406470 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Immunologic Deficiency Syndrome

Interventions

DRUG: Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™

Sponsor

Green Cross Corporation

Collaborators

[object Object]